Skip to main content
. Author manuscript; available in PMC: 2009 Jul 15.
Published in final edited form as: Cancer Res. 2008 Jul 15;68(14):5849–5858. doi: 10.1158/0008-5472.CAN-07-6130

Figure 4.

Figure 4

Therapeutic efficacy of TG2 siRNA with docetaxel. Nude mice were injected i.p. with HeyA8 (A) or HeyA8-MDR (B) or RMG2 (C) cells and randomly allocated to one of following groups (therapy beginning 1 week after tumor cell injection): empty liposomes, control siRNA-DOPC, control siRNA-DOPC with docetaxel, TG2 siRNA-DOPC, TG2 siRNA-DOPC with docetaxel. The animals were sacrificed when control mice became moribund (3–4 weeks after starting therapy) and necropsy was done. Error bars represent S.E.